[1] L.A. Torre, R.L. Siegel and A. Jemal, Lung Cancer Statistics, Adv Exp Med Biol 893 (2016), 1-19.
[2] J.A. Barta, C.A. Powell and J.P. Wisnivesky, Global Epidemiology of Lung Cancer, Ann Glob Health 85 (2019).
[3] J. Skřičková, B. Kadlec, O. Venclíček and Z. Merta, Lung cancer, Cas Lek Cesk 157 (2018), 226-236.
[4] H. Liu, Effect of Traditional Medicine on Clinical Cancer, Biomedical Journal of Scientific & Technical Research 30 (2020), 23548-23551.
[5] W. Haixia, M. Shu, Y. Li, W. Panpan, S. Kehuan, X. Yingquan, L. Hengrui, L. Xiaoguang, W. Zhidi and O. Ling, Effectiveness associated with different therapies for senile osteopo-rosis: a network Meta-analysis, J Tradit Chin Med 40 (2020), 17-27.
[6] Z. Chen, C.M. Fillmore, P.S. Hammerman, C.F. Kim and K.K. Wong, Non-small-cell lung cancers: a heterogeneous set of diseases, Nat Rev Cancer 14 (2014), 535-46.
[7] H. Hoy, T. Lynch and M. Beck, Surgical Treatment of Lung Cancer, Crit Care Nurs Clin North Am 31 (2019), 303-313.
[8] R. Li, Y. Huang, H. Liu, J.P. Dilger and J. Lin, Comparing volatile and intravenous anesthetics in a mouse model of breast cancer metastasis, American Association for Cancer Research, 2018, pp. 2162.
[9] R. Li, H. Liu, J.P. Dilger and J. Lin, Effect of Propofol on breast Cancer cell, the immune system, and patient outcome, BMC Anesthesiol 18 (2018), 77.
[10] H. Liu, J.P. Dilger and J. Lin, Effects of local anesthetics on cancer cells, Pharmacology & Therapeutics 212 (2020), 107558.
[11] H. Liu, A clinical mini-review: Clinical use of Local anesthetics in cancer surgeries, The Gazette of Medical Sciences 1 (2020), 030-034.
[12] M. Akkuş and E. Öner, Can local infiltration of lidocaine reduce the postoperative atrial fibrillation rate in patients undergoing lobectomy for lung cancer?, Acta Chir Belg 120 (2020), 265-270.
[13] S.N. Watanabe, K. Imai, T. Kimura, Y. Saito, S. Takashima, I. Matsuzaki, N. Kurihara, M. Atari, T. Matsuo, H. Iwai, Y. Sato, S. Motoyama, K. Nomura, T. Nishikawa and Y. Minamiya, Effect of lidocaine cream analgesia for chest drain tube removal after video-assisted thoracoscopic surgery for lung cancer: a randomized clinical trial, Reg Anesth Pain Med (2019).
[14] L. Zhang, R. Hu, Y. Cheng, X. Wu, S. Xi, Y. Sun and H. Jiang, Lidocaine inhibits the proliferation of lung cancer by regulating the expression of GOLT1A, Cell Prolif 50 (2017).
[15] H. Sun and Y. Sun, Lidocaine inhibits proliferation and metastasis of lung cancer cell via regulation of miR-539/EGFR axis, Artif Cells Nanomed Biotechnol 47 (2019), 2866-2874.
[16] T.P. Wall, P.D. Crowley, A. Sherwin, A.G. Foley and D.J. Buggy, Effects of Lidocaine and Src Inhibition on Metastasis in a Murine Model of Breast Cancer Surgery, Cancers (Basel) 11 (2019).
[17] H. Liu, J.P. Dilger and J. Lin, Lidocaine Suppresses Viability and Migration of Human Breast Cancer Cells: TRPM7 as A Target for Some Breast Cancer Cell Lines, Cancers (Basel) 13 (2021), 234.
[18] L. Ye, Y. Zhang, Y.J. Chen and Q. Liu, Anti-tumor effects of lidocaine on human gastric cancer cells in vitro, Bratisl Lek Listy 120 (2019), 212-217.
[19] H. Liu, A Prospective for the Potential Effect of Local Anesthetics on Stem-Like Cells in Colon Cancer, Biomedical Journal of Scientific & Technical Research 25 (2020), 18927-18930.
[20] W. Siekmann, E. Tina, A.K. Von Sydow and A. Gupta, Effect of lidocaine and ropivacaine on primary (SW480) and metastatic (SW620) colon cancer cell lines, Oncol Lett 18 (2019), 395-401.
[21] A.C. Bundscherer, M. Malsy, D.I. Bitzinger, C.H. Wiese, M.A. Gruber and B.M. Graf, Effects of Lidocaine on HT-29 and SW480 Colon Cancer Cells In Vitro, Anticancer Res 37 (2017), 1941-1945.
[22] G. D'Agostino, A. Saporito, V. Cecchinato, Y. Silvestri, A. Borgeat, L. Anselmi and M. Uguccioni, Lidocaine inhibits cytoskeletal remodelling and human breast cancer cell migration, Br J Anaesth 121 (2018), 962-968.
[23] S. Cavallaro, CXCR4/CXCL12 in non-small-cell lung cancer metastasis to the brain, Int J Mol Sci 14 (2013), 1713-27.
[24] M.C. Smith, K.E. Luker, J.R. Garbow, J.L. Prior, E. Jackson, D. Piwnica-Worms and G.D. Luker, CXCR4 regulates growth of both primary and metastatic breast cancer, Cancer Res 64 (2004), 8604-12.
[25] F. Bachelerie, A. Ben-Baruch, A.M. Burkhardt, C. Combadiere, J.M. Farber, G.J. Graham, R. Horuk, A.H. Sparre-Ulrich, M. Locati, A.D. Luster, A. Mantovani, K. Matsushima, P.M. Murphy, R. Nibbs, H. Nomiyama, C.A. Power, A.E. Proudfoot, M.M. Rosenkilde, A. Rot, S. Sozzani, M. Thelen, O. Yoshie and A. Zlotnik, International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors, Pharmacol Rev 66 (2014), 1-79.
[26] B. Furusato, A. Mohamed, M. Uhlén and J.S. Rhim, CXCR4 and cancer, Pathol Int 60 (2010), 497-505.
[27] Z. Wang, J. Sun, Y. Feng, X. Tian, B. Wang and Y. Zhou, Oncogenic roles and drug target of CXCR4/CXCL12 axis in lung cancer and cancer stem cell, Tumour Biol 37 (2016), 8515-28.
[28] X. Li, B. Peng, X. Zhu, P. Wang, Y. Xiong, H. Liu, K. Sun, H. Wang, L. Ou, Z. Wu, X. Liu, H. He, S. Mo, X. Peng, Y. Tian, R. Zhang and L. Yang, Changes in related circular RNAs following ERbeta knockdown and the relationship to rBMSC osteogenesis, Biochem Biophys Res Commun 493 (2017), 100-107.
[29] Z. Wu, L. Ou, C. Wang, L. Yang, P. Wang, H. Liu, Y. Xiong, K. Sun, R. Zhang and X. Zhu, Icaritin induces MC3T3-E1 subclone14 cell differentiation through estrogen receptor-mediated ERK1/2 and p38 signaling activation, Biomed Pharmacother 94 (2017), 1-9.
[30] X. Liu, H. Liu, Y. Xiong, L. Yang, C. Wang, R. Zhang and X. Zhu, Postmenopausal osteoporosis is associated with the regulation of SP, CGRP, VIP, and NPY, Biomed Pharmacother 104 (2018), 742-750.
[31] J.S. Plested, P.A. Coull and M.A. Gidney, ELISA, Methods Mol Med 71 (2003), 243-61.
[32] Y. Zhang, X. Zhan, J. Xiong, S. Peng, W. Huang, R. Joshi, Y. Cai, Y. Liu, R. Li, K. Yuan, N. Zhou and W. Min, Temperature-dependent cell death patterns induced by functionalized gold nanoparticle photothermal therapy in melanoma cells, Sci Rep 8 (2018), 8720.
[33] J. Phuchareon, F. McCormick, D.W. Eisele and O. Tetsu, EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function, Proc Natl Acad Sci U S A 112 (2015), E3855-63.
[34] L. Farilla, A. Bulotta, B. Hirshberg, S. Li Calzi, N. Khoury, H. Noushmehr, C. Bertolotto, U. Di Mario, D.M. Harlan and R. Perfetti, Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets, Endocrinology 144 (2003), 5149-58.
[35] H. Liu, Y. Xiong, H. Wang, L. Yang, C. Wang, X. Liu, Z. Wu, X. Li, L. Ou, R. Zhang and X. Zhu, Effects of water extract from epimedium on neuropeptide signaling in an ovariectomized osteoporosis rat model, J Ethnopharmacol 221 (2018), 126-136.
[36] L. Li, L. He, Y. Wu and Y. Zhang, Carvacrol affects breast cancer cells through TRPM7 mediated cell cycle regulation, Life Sciences 266 (2021), 118894.
[37] P. Mehta, Semi-dry protein transfer and immunodetection of P-selectin using an antibody to its C-terminal tag, Methods Mol Biol 536 (2009), 229-35.
[38] H. Liu, Y. Xiong, X. Zhu, H. Gao, S. Yin, J. Wang, G. Chen, C. Wang, L. Xiang, P. Wang, J. Fang, R. Zhang and L. Yang, Icariin improves osteoporosis, inhibits the expression of PPARgamma, C/EBPalpha, FABP4 mRNA, N1ICD and jagged1 proteins, and increases Notch2 mRNA in ovariectomized rats, Exp Ther Med 13 (2017), 1360-1368.
[39] J. Song, W. Song and L. Zhang, LncRNA RP1-85F18. 6 affects osteoblast cells by regulating the cell cycle, Open Life Sciences 15 (2020), 951-958.
[40] G. Chen, C. Wang, J. Wang, S. Yin, H. Gao, L.U. Xiang, H. Liu, Y. Xiong, P. Wang, X. Zhu, L.I. Yang and R. Zhang, Antiosteoporotic effect of icariin in ovariectomized rats is mediated via the Wnt/beta-catenin pathway, Exp Ther Med 12 (2016), 279-287.
[41] F. Cappiello, B. Casciaro and M.L. Mangoni, A Novel In Vitro Wound Healing Assay to Evaluate Cell Migration, J Vis Exp (2018).
[42] M. Ding, H. Zhan, X. Liao, A. Li, Y. Zhong, Q. Gao, Y. Liu, W. Huang and Z. Cai, Enhancer RNA - P2RY2e induced by estrogen promotes malignant behaviors of bladder cancer, Int J Biol Sci 14 (2018), 1268-1276.
[43] E.E. Pepperell and S.M. Watt, A novel application for a 3-dimensional timelapse assay that distinguishes chemotactic from chemokinetic responses of hematopoietic CD133(+) stem/progenitor cells, Stem Cell Res 11 (2013), 707-20.
[44] R. Zantl and E. Horn, Chemotaxis of slow migrating mammalian cells analysed by video microscopy, Methods Mol Biol 769 (2011), 191-203.
[45] H. Liu, J.P. Dilger and J. Lin, The Role of Transient Receptor Potential Melastatin 7 (TRPM7) in Cell Viability: A Potential Target to Suppress Breast Cancer Cell Cycle, Cancers (Basel) 12 (2020).
[46] M.W. Roe, J.J. Lemasters and B. Herman, Assessment of Fura-2 for measurements of cytosolic free calcium, Cell Calcium 11 (1990), 63-73.
[47] B. Chazotte, Labeling cytoskeletal F-actin with rhodamine phalloidin or fluorescein phalloidin for imaging, Cold Spring Harb Protoc 2010 (2010), pdb.prot4947.
[48] R. Li, C. Xiao, H. Liu, Y. Huang, J.P. Dilger and J. Lin, Effects of local anesthetics on breast cancer cell viability and migration, BMC cancer 18 (2018), 666.
[49] T. Liang, B. Wang, J. Li and Y. Liu, LINC00922 Accelerates the Proliferation, Migration and Invasion of Lung Cancer Via the miRNA-204/CXCR4 Axis, Med Sci Monit 25 (2019), 5075-5086.
[50] Y. Wu, Q.W. Shen, Y.X. Niu, X.Y. Chen, H.W. Liu and X.Y. Shen, LncNORAD interference inhibits tumor growth and lung cancer cell proliferation, invasion and migration by down-regulating CXCR4 to suppress RhoA/ROCK signaling pathway, Eur Rev Med Pharmacol Sci 24 (2020), 5446-5455.
[51] J. Zuo, M. Wen, S. Li, X. Lv, L. Wang, X. Ai and M. Lei, Overexpression of CXCR4 promotes invasion and migration of non-small cell lung cancer via EGFR and MMP-9, Oncol Lett 14 (2017), 7513-7521.
[52] J.A. Burger, D.J. Stewart, O. Wald and A. Peled, Potential of CXCR4 antagonists for the treatment of metastatic lung cancer, Expert Rev Anticancer Ther 11 (2011), 621-30.
[53] W. Zhou, S. Guo, M. Liu, M.E. Burow and G. Wang, Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy, Curr Med Chem 26 (2019), 3026-3041.
[54] J.Y. Guo, C.H. Chiu, M.J. Wang, F.A. Li and J.Y. Chen, Proteoglycan serglycin promotes non-small cell lung cancer cell migration through the interaction of its glycosaminoglycans with CD44, J Biomed Sci 27 (2020), 2.
[55] C.Y. Wang, C.S. Huang, Y.P. Yang, C.Y. Liu, Y.Y. Liu, W.W. Wu, K.H. Lu, K.H. Chen, Y.L. Chang, S.D. Lee and H.C. Lin, The subpopulation of CD44-positive cells promoted tumorigenicity and metastatic ability in lung adenocarcinoma, J Chin Med Assoc 82 (2019), 196-201.
[56] H.B. Zhang, B. Shen, Z.C. Ma, Y.Y. Xu, Y.L. Lou and M. Chen, MiR-593-5p inhibited proliferation and migration of lung adenocarcinoma by targeting ICAM-1, Eur Rev Med Pharmacol Sci 24 (2020), 4298-4305.
[57] Z. He, L. Jia, Y. Lyu, G. Dong, Y. Jiang and J. Zheng, [Increased expression of transendothelial migration-related molecules CCL4, ICAM-1 and VCAM-1 in lung tissue after surgical removal of mouse tumor-bearing lymph node], Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 36 (2020), 699-703.
[58] Q.M. Shen, H.Y. Wang and S. Xu, MARCH9 Suppresses Lung Adenocarcinoma Progression by Downregulating ICAM-1, Cell Physiol Biochem 50 (2018), 92-107.
[59] F. Le Pimpec Barthes, P. Mordant, C. Pricopi, C. Foucault, A. Dujon and M. Riquet, [The place of surgery in metastatic non-small cell lung cancer], Rev Mal Respir 29 (2012), 376-83.
[60] T. Liu, H. Liu, G. Wang, C. Zhang and B. Liu, Survival of M1a Non-Small Cell Lung Cancer Treated Surgically: A Retrospective Single-Center Study, Thorac Cardiovasc Surg 63 (2015), 577-82.
[61] H. Liu, Nav channels in cancers: Nonclassical roles, Global Journal of Cancer Therapy 6 (2020), 5.
[62] H.W. Wang, L.Y. Wang, L. Jiang, S.M. Tian, T.D. Zhong and X.M. Fang, Amide-linked local anesthetics induce apoptosis in human non-small cell lung cancer, J Thorac Dis 8 (2016), 2748-2757.
[63] M. Yousefi, T. Bahrami, A. Salmaninejad, R. Nosrati, P. Ghaffari and S.H. Ghaffari, Lung cancer-associated brain metastasis: Molecular mechanisms and therapeutic options, Cell Oncol (Dordr) 40 (2017), 419-441.
[64] E.A. Kotteas, P. Boulas, I. Gkiozos, S. Tsagkouli, G. Tsoukalas and K.N. Syrigos, The intercellular cell adhesion molecule-1 (icam-1) in lung cancer: implications for disease progression and prognosis, Anticancer Res 34 (2014), 4665-72.
[65] T. Piegeler, E.G. Votta-Velis, G. Liu, A.T. Place, D.E. Schwartz, B. Beck-Schimmer, R.D. Minshall and A. Borgeat, Antimetastatic potential of amide-linked local anesthetics: inhibition of lung adenocarcinoma cell migration and inflammatory Src signaling independent of sodium channel blockade, Anesthesiology 117 (2012), 548-59.
[66] K. Princen, S. Hatse, K. Vermeire, E. De Clercq and D. Schols, Evaluation of SDF-1/CXCR4-induced Ca2+ signaling by fluorometric imaging plate reader (FLIPR) and flow cytometry, Cytometry A 51 (2003), 35-45.
[67] N.W. Ikebuchi and D.M. Waisman, Calcium-dependent regulation of actin filament bundling by lipocortin-85, J Biol Chem 265 (1990), 3392-400.
[68] A.R. van Vliet, F. Giordano, S. Gerlo, I. Segura, S. Van Eygen, G. Molenberghs, S. Rocha, A. Houcine, R. Derua, T. Verfaillie, J. Vangindertael, H. De Keersmaecker, E. Waelkens, J. Tavernier, J. Hofkens, W. Annaert, P. Carmeliet, A. Samali, H. Mizuno and P. Agostinis, The ER Stress Sensor PERK Coordinates ER-Plasma Membrane Contact Site Formation through Interaction with Filamin-A and F-Actin Remodeling, Mol Cell 65 (2017), 885-899.e6.
[69] T. Oda, M. Iwasa, T. Aihara, Y. Maéda and A. Narita, The nature of the globular- to fibrous-actin transition, Nature 457 (2009), 441-5.
[70] D. Yang and J. Kim, Emerging role of transient receptor potential (TRP) channels in cancer progression, BMB Rep 53 (2020), 125-132.
[71] H. Liu, A prospective for the role of two-pore channels in breast cancer cells, Global Journal of Cancer Therapy 6 (2020), 001--003.